Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 511-520 of 639 results
Front. Mol. Neurosci., 2024 • August 20, 2024
This study introduces C286, an oral RARβ agonist, as a potential therapy for spinal cord injuries. It demonstrates that C286 modulates gene expression and ECM molecules to promote tissue repair and ax...
KEY FINDING: C286 upregulates tenascin-C, integrin-α9, and osteopontin in the injured spinal cord, promoting nerve regeneration.
Advanced Science, 2024 • September 28, 2024
This study demonstrates that traumatic pathological vascular remodeling occurs during the chronic phase of injury, characterized by enlarged vessel diameter, disruption of blood-spinal cord barrier, e...
KEY FINDING: Traumatic SCI leads to pathological vascular remodeling, including enlarged vessel diameter and disruption of the blood-spinal cord barrier.
Bioeng Transl Med, 2024 • May 1, 2024
The study developed injectable hydrogels for local, controlled release of protein therapeutics into tissue. The hydrogel, featuring slowly hydrolyzing linkers, prolongs the therapeutic effect, minimiz...
KEY FINDING: Anti-CD47 monoclonal antibodies incorporated into subsurface-injected hydrogel solutions exhibited cytotoxic activity against infiltrative high-grade glioma xenografts in the rodent brain.
Front. Bioeng. Biotechnol., 2024 • November 21, 2024
This study constructs a Dual-Phase SilMA hydrogel scaffold (DPSH), incorporating PLGA microspheres encapsulating neurotrophin-3 (NT-3) and angiotensin (Ang-(1–7), and neural stem cells. In vitro studi...
KEY FINDING: Ang-(1–7) significantly induced M2 microglia polarization by 1.8-fold (p < 0.0001), effectively reducing inflammation.
Global Spine Journal, 2024 • January 1, 2024
This study evaluated the effects of different doses of erythropoietin (EPO) and magnitudes of trauma on neural regeneration in rats with spinal cord injuries. Rats were subjected to varying degrees of...
KEY FINDING: Animals receiving a higher dose of erythropoietin (5000 IU/kg) and suffering minor trauma (12.5 mm impact height) showed better and faster neurological recovery.
Nature Communications, 2024 • December 8, 2024
The study identifies SCM-198 as a potential therapeutic agent for advanced acute liver failure (ALF). SCM-198 demonstrates a remarkable 100% survival rate in murine ALF models, even when administered ...
KEY FINDING: SCM-198 treatment resulted in a 100% survival rate in murine ALF models, even when administered 24 hours after ALF was established.
Journal of Nanobiotechnology, 2025 • January 22, 2025
This study engineered a methylprednisolone substitution lipid nanoparticle (MP-LNP) encapsulating C3 transferase mRNA (MP-LNP-C3) for SCI treatment. The MP-LNP effectively transfected neurons and achi...
KEY FINDING: The incorporation of C3 transferase mRNA into MP-LNPs does not compromise the structural integrity of the nanoparticles, ensuring efficient mRNA expression within the spinal cord.
Materials Today Bio, 2025 • February 4, 2025
Spinal cord injury (SCI) presents a significant neurological challenge, spurring interest in novel treatment strategies like tissue engineering and stem cell engineering. Combining drug and cell deliv...
KEY FINDING: Tissue engineering strategies can address the limitations of conventional SCI treatments by delivering drugs and cells with specific effects to the injury site.
Metab Brain Dis, 2015 • April 1, 2015
The review provides a historical overview of SCI treatment, from ancient times to the present day, highlighting the shift from surgical interventions to pharmacological approaches. The complex pathoph...
KEY FINDING: Oxycyte, an oxygen carrier, significantly increased oxygen saturation and reduced apoptotic cell death in a rat model of spinal cord injury.
The Journal of Neuroscience, 2015 • January 21, 2015
This study investigates the potential of using clinically approved medications to stimulate remyelination by activating monocytes, macrophages, and microglia. Amphotericin B (AmpB) was identified as a...
KEY FINDING: Amphotericin B (AmpB) activates monocytes, macrophages, and microglia through MyD88/TRIF signaling.